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Abstract  
Targeted tumour therapy is in the focus of recent cancer research. GnRH analogues are able to 
deliver anticancer agents selectively into tumour cells which highly express GnRH receptors. 
However, the effectiveness of different analogues as targeting moiety in drug delivery 
systems is rarely compared and the investigated types of cancers are also limited. Therefore, 
we prepared selectively labelled, fluorescent derivatives of GnRH-I, -II, and -III analogues 
which successfully used for drug targeting. In this manuscript we investigated these analogues 
solubility, stability, passive membrane permeability and compared their cellular uptake by 
various cancer cells.  
We found that these labelled GnRH conjugates provide great detectability, without undesired 
cytotoxicity and passive membrane permeability. The introduced experiments with these 
conjugates proved their reliable tracking, quantification and comparison. Cellular uptake 
efficiency was studied on human breast, colon, pancreas and prostate cancer cells (MCF-7, 
HT-29, BxPC-3, LNCaP) and on dog kidney cells (MDCK). Each of the three conjugates 
were taken up by GnRH-I receptor expressing cells, but the different cells preferred different 
analogues. Furthermore, we demonstrated for the first time the high cell surface expression of 
GnRH-I receptors and the effective cellular uptake of GnRH analogues on human pharynx 
tumour (Detroit-562) cells. 
In summary, our presented results detail that the introduced conjugates could be innovative 
tools for the examination of the GnRH based drug delivery systems on various cells and offer 
novel information about these peptides. 
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Abbreviations 
Alloc Allyloxycarbonyl 
COMU (1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluorophosphate 
DCM Dichloromethane 
DMEM Dulbecco's Modified Eagle's medium 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
FACS Fluorescence Activated Cell Sorting  
FITC Fluorescein isothiocyanate 
Fmoc Fluorenylmethyloxycarbonyl 
GnRH Gonadotropin-releasing hormone 
GnRH-R Gonadotropin-releasing hormone receptor 
GnRH-I-R Type I gonadotropin-releasing hormone receptor 
ivDde 1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl 
MDCK Madin-Darby Canine Kidney 
MFI Median Fluorescence Intensity 
NMM 4-Methylmorpholine 
PAMPA Parallel Artificial Membrane Permeability Assay  
PBS Phosphate-buffered saline 
RPMI Roswell Park Memorial Institute 
TFA Trifluoroacetic acid 
TIPS Triisopropylsilane 
 
Introduction 
Cancer is the second leading cause of death in the developed countries [1]. Among treatment 
options for cancer one of the most promising and developing procedure is the targeted 
chemotherapy, based on the tumour selective or over-expressed receptors. The high 
expression of gonadotropin releasing hormone receptor (also called luteinizing hormone 
releasing hormone receptor) has been identified in many types of cancer [2–4]. Therefore the 
natural and artificial ligands of GnRH receptors are extensively studied as tumour targeting 
systems [5–8]. 
Human pituitary GnRH-R has crucial role in the control of the reproductive system, and it is a 
well-known molecular target in the treatment of reproduction-related diseases [9]. GnRH 
analogues are widely and successfully used for the treatment of different hormone related 
pathologies based on their ability to suppress the hypothalamic–pituitary–gonadal axis [10]. 
GnRH receptors are also expressed in number of cancer tissues, either related or unrelated to 
the reproductive system [11]. It was indicated that GnRH and its receptors are a part of an 
autocrine/paracrine regulatory system of cell proliferation in malignant tumours [11–13]. In 
addition, the proliferation can be inhibited by agonist or antagonist analogues of GnRH in a 
dose and time dependent manner both in vitro and in vivo [12,14]. Furthermore, GnRH 
derivatives can be used as homing devices to deliver anticancer drugs into cancer cells 
expressing GnRH receptors [15]. Cytotoxic drug - GnRH conjugates could dramatically 
improve the antitumour efficiency of GnRH analogues and represent a very promising 
therapeutic approach for certain tumours. Schally and co-workers developed potent GnRH-
drug conjugates, including [D-Lys
6
]-GnRH-I-doxorubicin which is in Phase II or III Clinical 
Trial for several types of cancer [8]. 
Besides GnRH-I, a second native isoform of GnRH (first isolated from chicken (Gallus gallus 
domesticus) [16]) was identified in humans [17]. The GnRH-II receptor was revealed in 
various species including nonhuman primates, but the existence of GnRH-II receptor in the 
human organism is still controversial [18]. Fister and co-workers reported that GnRH-II 
antagonists are able to bind to the GnRH-I receptor (GnRH-I-R), and their binding affinity are 
similar to the GnRH-I antagonist Cetrorelix [19]. Furthermore, Montagnani et al. reported that 
the effect of GnRH-II was mediated by GnRH-I-R on prostate cancer cells [20]. GnRH-II had 
strong antiproliferative effect and induced apoptosis in endometrial, ovarian, breast and 
prostate cancer cell lines as well [18–21]. Gründker et al. reported that on the human ovarian 
cancer cell line SK-OV-3, which does not express GnRH-I-R, the GnRH-I antagonist 
Cetrorelix and GnRH-II had strong antiproliferative effect [22]. These results suggested that 
the antiproliferative effect of GnRH-II in endometrial and ovarian cancer cells were not 
mediated through the GnRH-I-R [22]. Therefore, the GnRH-I-R seems not to be the only 
target for GnRH-II agonists on certain cancer cells [18]. Besides, the cytotoxic conjugates of 
[D-Lys
6
]-GnRH-II were also described to be effective antitumour agents [23]. 
A third isoform of GnRH was isolated from sea lamprey (Petromyzon marinus) [24]. 
Lamprey GnRH-III binds to both GnRH-I and GnRH-II receptors but with lower efficacy than 
their native ligands [25]. Therefore, it is a weak GnRH agonist which has insignificant 
endocrine effect in mammals. In addition it can recognize not only the high-, but also the low-
affinity binding sites of GnRH receptors on cancer cells [25]. In experimental setups, GnRH-
III significantly suppressed the proliferation of human cancer cells which overexpress GnRH-
R [26]. Therefore, also daunorubicin containing GnRH-III conjugates were synthesized and 
investigated in vitro and in vivo [27–29]. These conjugates were well tolerated and had 
significant antitumour effect on colon carcinoma-bearing mice [29]. On castration-resistant 
prostate cancer cells GnRH-III-daunorubicin conjugates inhibited tumour cell proliferation 
and exerted their antitumour effect through the activation of GnRH-I-R [28]. Based on these 
observations GnRH-III-based peptides are considered promising targeting moieties for the 
preparation of anticancer drug delivery systems. 
Although hundreds of publications has been reported about GnRH and GnRH conjugates 
since it was discovered [30], there are only a few experiments with fluorescently labelled 
GnRH derivatives [31]. The variety of the tested cell lines has been also limited yet, and the 
results coming out from different studies are usually not comparable due to the different 
experimental parameters. 
Our idea was that benefits of fluorescently-labelled GnRH analogues could contribute to the 
development of novel tumour targeting GnRH–drug conjugates, besides could help to identify 
new therapeutic targets and offer novel information about these peptides. Indeed, selectively 
labelled peptides have excellent tracking properties and allow their reliable quantification. 
Quantifying the uptake of these analogues may predict the adequacy of a given cancer culture 
for GnRH targeted therapy.  
Based on these considerations we selected three effective GnRH analogues, which 
successfully used for drug delivery ([D-Lys
6
]-GnRH-I, [D-Lys
6
]-GnRH-II and GnRH-III) and 
selectively labelled them with FITC. In the present manuscript the syntheses of [D-
Lys
6
(FITC)]-GnRH-I, [D-Lys
6
(FITC)]-GnRH-II and [Lys
8
(FITC)]-GnRH-III were described 
and their characterization, solubility, stability, cellular permeability, cytotoxicity and cellular 
uptake properties were studied. To demonstrate the usability of these conjugates, we tested 
them on GnRH-I-R expressing LNCaP (prostate), MCF-7 (breast), BxPC-3 (pancreas) and 
HT-29 (colon) tumour cell lines [18,32–34], and involved a previously not investigated 
pharynx tumour cell line, the Detroit-562 into the experiments. We investigated the presence 
of the GnRH-I-R on the featured pharynx tumour and evaluated its susceptibility for GnRH 
targeted therapy.  
 
Materials and Methods 
 Synthesis of FITC labelled GnRH conjugates 
All amino acid derivatives and reagents were purchased from Sigma-Aldrich Ltd. (Budapest, 
Hungary). The solvents (acetonitrile, ethanol, methanol, pyridine, diethyl-ether, DCM, DMF) 
were purchased from Reanal Ltd. (Budapest, Hungary). All reagents and solvents were 
reagent grade or the highest available purity.  
GnRH peptides were synthesized manually on H-Rink Amide ChemMatrix
®
 resin using 
standard Fmoc strategy. The following amino acid derivatives were applied: Fmoc-Gly-OH, 
Fmoc-Pro-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-D-Lys(Alloc)-OH, Fmoc-
Tyr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Trp(Boc)-OH, Fmoc His(Trt)-OH, Fmoc-
Lys(ivDde)-OH, Fmoc-Asp(OtBu)-OH. Pyroglutamic acide (pGlu) was attached to the N-
terminus of the peptide without any protection. All couplings employed three equivalents of 
amino acid derivate, with COMU and NMM at room temperature, for 20 min. Coupling 
involved minimal preactivation times. The Fmoc group was removed with 20% piperidine in 
DMF. 
The Alloc protecting group was removed in DCM by using 
tetrakis(triphenylphosphine)palladium(0) and phenylsilane under inert atmosphere. After 
deprotection, sodium N,N-diethyldithiocarbamate in DMF was used for the removal of 
palladium. The ivDde protecting group was cleaved with DMF containing 2% hydrazine 
hydrate. For fluorescent labelling the free -amino groups of Lys or D-Lys residues 1.1 
equivalent of FITC was dissolved in a mixture of pyridine/DMF/DCM (12:7:5 ratio) and the 
solution was added to the resin. The conjugations were carried out overnight under inert 
atmosphere. The FITC labelled peptides were cleaved from the resins with 
TFA/phenol/water/thioanisole/TIPS (82.5:5:5:5:2.5 ratio) mixture for 2 hours at room 
temperature. The filtrates were precipitated in cold diethyl ether, the yellow precipitates were 
filtered and dried under vacuum to give the crude peptide conjugate. Crude peptide conjugates 
were purified by semi-preparative RP-HPLC, and the pure compounds were characterized by 
analytical RP-HPLC and ESI-mass spectrometry. 
 
High performance liquid chromatography  
Analytical and preparative RP-HPLC were performed on a Jasco HPLC system (ABL&E-
JASCO Hungary Ltd., Budapest, Hungary). The crude products were purified on a 
Phenomenex Gemini C18 column (150 mm/21.4 mm, 5 µm). For the purification, gradient 
elution (0 min 0% B, 5 min 20% B, and 50 min 40% B) of eluent A (0.1% TFA in water) and 
eluent B (acetonitrile) was used at a flow rate of 10 mL/min.  
The purity, aqueous solubility, stability, and permeability experiments of the GnRH peptides 
were measured by analytical HPLC, using Technokroma® Mediterranea Sea C18 column (50 
mm/4.0 mm, 3 µm). Linear gradient elution (0 min 0%, 12 min 50% B) of eluent A (0.1% 
TFA in water) with eluent B (acetonitrile) was used at a flow rate of 1 mL/min. Peaks were 
detected by UV detector at λ=220 nm. 
  
Mass spectrometry 
Mass spectrometric analyses were carried out on a Waters Q-TOF Premier mass spectrometer 
(Waters Ltd., Budapest, Hungary). Electrospray ion source (ESI/MS) was used to perform MS 
measurements in positive ion mode in a range of 100-1800 Da. Samples were dissolved in 
acetonitrile/water (1:2 ratio) containing 0.1% TFA and introduced into the instrument. The 
ESI-MS conditions are detailed in the Supporting Information. 
 
Solubility experiment 
Solubility of FITC-GnRH conjugates was measured in PBS (pH: 7.4, without Ca
2+
 and Mg
2+
, 
Lonza Group Ltd. Basel, Switzerland). 10 mM DMSO stock solutions were diluted to 200 µM 
in PBS (2% final DMSO concentration). Samples were incubated for 24 hours at 25°C and 
centrifuged them for 30 minutes at 13.000 rpm. Supernatants were measured by HPLC-UV. 
External standard method was used to construct calibration curves and quantify the 
concentrations in supernatants. Each experiment was repeated four times. 
 
Stability experiment 
10 mM DMSO stock solutions were diluted to 40 µM in cell culture medium (RPMI). RPMI 
solutions incubated for 24 hours at 37°C. The stability of the compounds was monitored by 
HPLC-UV. 
 
Cell cultures 
NIH/3T3 (mouse fibroblast), LNCaP (prostate), MCF-7 (breast), BxPC-3 (pancreas), HT-29 
(colon) and Detroit-562 (pharynx) cell lines were obtained from American Type Culture 
Collection (Rockville, MD U.S). MDCK (Madin–Darby canine kidney) wild type cell line 
was provided by Alfred Schinkel (Netherlands Cancer Institute, Amsterdam, The 
Netherlands). Cell lines maintained in the ATCC
®
 recommended mediums (Lonza Group 
Ltd., Basel, Switzerland), supplemented with 10% (v/v) fetal bovine serum (Lonza Group 
Ltd.) and antibiotics (MycoZap™ Plus-CL, Lonza Group Ltd.) in a humidified, 5% CO2 
atmosphere incubator at 37°C. 
 
Parallel artificial membrane permeability assay 
BD Gentest™ Pre-Coated PAMPA plate system was gifted by Vichem Chemie Ltd. 
(Budapest, Hungary). 10 mM DMSO stock solutions were diluted to 40 µM in PBS and 
loaded into the donor plate. The assembly was incubated in a plate shaker (BioSan Thermo-
Shaker PST-60HL, BioSan, Riga, Latvia) at 250 rpm for 5 h at 25°C. Concentrations were 
determined by UV-VIS spectroscopy (BioTek Synergy 2 Multi-Mode Reader, BioTek U.S, 
Winooski, VT U.S). Each assay was repeated twice. The calculation formulas are described in 
the Supporting Information. 
 
MDCK permeability assay 
Costar® Transwell® Permeable Support 12 well plates (12 mm insert, 0.4 µm polyester 
membrane) were obtained from Zenon Bio Ltd. (Szeged, Hungary). MDCK cells seeded onto 
the insert membranes at a density of about 10
5
 cells/insert (in 0.5 mL medium). After growing 
for 4 days, the conﬂuence of the cell monolayers were conﬁrmed by microscope and 
measurement of transepithelial electrical resistance (EVOM2, Epithelial Voltohmmeter for 
TEER, World Precision Instruments, FL U.S) 10 mM stock solutions of test compounds were 
prepared in DMSO and diluted with buffer solution to 10 µM before transport experiments. 
The plates were incubated in a plate shaker (BioSan Thermo-Shaker PST-60HL), at 250 rpm 
for 60 min at 37 °C. Aliquots were collected from the chambers and the concentration was 
quantiﬁed by HPLC-UV. Each experiment was repeated two times. 
 
Cytotoxicity assay 
Reagents were purchased from Sigma-Aldrich Ltd. NIH/3T3 cells were seeded into 96 well 
plates at a density of 10
4
 cells/well and were treated with the compounds for 24 hours at 40 
µM in complete medium. After treatment, medium was removed and 50 μL PBS containing 5 
mg/mL [3-(4,5-dimethylthiaziazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] (MTT) was 
added to the wells and cells were incubated for 2 hours in 37
o
C. The produced tetrazolium 
crystals were dissolved in isopropanol containing 10% (v/v) Triton X-100 and 1% (v/v) 0.1 N 
HCl. Absorbance was measured at 570 nm and 690 nm (BioTek, Synergy 2 Multi-Mode 
Reader). The 690 nm data was subtracted from the 570 nm for each well. Each experiment 
was repeated three times. 
 
Western blot analysis 
Cells were washed twice with ice-cold PBS and lysed in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% (v/v) NP-40, 0.5% (m/v) sodium-
deoxycholate, 0.1% (m/v) sodium dodecyl sulfate, 2 mM EDTA, 2 mM EGTA) 
complemented with 50 mM NaF, 1 mM dithiothreitol, 1mM sodium-ortovanadate (reagents 
were obtained from Sigma Aldrich Ltd.) and protease inhibitor cocktail (Calbiochem
® 
Cat. 
No.:539134) for 30 minutes on ice. Lysates were centrifuged with 10 000 g at 4°C for 15 
minutes. Equal amounts of protein (40 μg) were subjected to SDS-PAGE and 
electrotransferred to polyvinylidene-difluoride (PVDF) membranes (Bio-Rad Ltd., Budapest, 
Hungary). Membranes were probed with GnRH-I-R specific primary antibody (Proteintech™, 
Catalog number: 19950-1-AP, Rosemont, IL U.S) and α-tubulin primary antibody (Sigma 
Aldrich Ltd.) at 4°C overnight, then with horse radish peroxidase (HRP) conjugated 
secondary antibody (Cell Signaling Technology Inc., Danvers, MA U.S) for 1 h at room 
temperature. Bands were visualized by Enhanced Chemiluminescence (ECL) detection 
system (Western Lightning Plus-ECL, PerkinElmer, Waltham, MA U.S). Each experiment 
was repeated three times. 
 
Confocal laser scanning microscopy 
Cells were seeded on Ibidi® µ-Slide 8 Well microscopic slides (Zenon Bio Ltd., Szeged, 
Hungary) in complete medium and let to adhere overnight. At the immunocytochemistry 
experiments, cells were fixed with 4% paraformaldehyde, washed with PBS, incubated with a 
primary antibody specific for GnRH-I receptor for 1 hour (Proteintech™, Catalog number: 
19950-1-AP), then cells were washed with PBS again and incubated with a Alexa Fluor 546 
conjugated secondary antibody (Catalog number: A-11035, Thermo Fisher Scientific, 
Waltham, MA U.S) for 1 hour. Draq5™ (Thermo Fisher Scientific) fluorescent probe solution 
was added to the cells, then they were incubated for 10 min, washed with PBS and mounted 
with mounting media afterwards.  
At the uptake experiments of GnRH conjugates, cells were treated with 10 µM conjugates and 
incubated for 5 h at 37°C. Treatment medium was removed, the cells were washed with PBS 
and fixed with 4% formaldehyde. Cells were washed with PBS followed by adding Draq5™ 
and they were incubated for 10 min, washed with PBS and mounted with mounting media 
afterwards.  
Images of cells were acquired under an oil immersion objective with confocal laser 
microscope (Zeiss Confocal LSM 710, Carl Zeiss AG, Oberkochen, Germany) 
 
Flow cytometry analysis  
Approximately 10
5
 cells were seeded per well to 24 well plates in complete medium and let to 
adhere overnight. Next day cells were treated with conjugates or vehicle (DMSO) at the 
indicated concentrations in full medium and incubated for 1 h or 5 h. After incubation 
supernatant was discarded, trypsin was added for 10 min, at 37°C. Cells were pelleted (250 g, 
4 min, RT) in FACS tubes, resuspended in 300 µL PBS and kept at 4°C for the rest of the 
experiment. The fluorescence intensity of the conjugate-stained cells was analysed by a FACS 
Calibur flow cytometer (BD Biosciences, San Jose, CA) using the FL1 channel. Data were 
evaluated by CellQuest Pro software (BD Biosciences). The total uptake (relative MFI values, 
based on DMSO control) of conjugates were calculated at 1 µM, after 1 hour and 5 hours 
incubations. The uptake was calculated at 1 µM and 10 µM, between the 1 hour and 5 hours 
incubations, as well. Calculation formulas are described in the Supporting Information. Each 
experiment was repeated three times. 
 
Results and Discussion 
GnRH analogues and their cytotoxic conjugates were reported as effective antitumour agents. 
Numerous studies were published about GnRH based tumour targeting, and many 
radiolabelled GnRH analogues were investigated and reported as well. However, there is only 
a little information available about fluorescently labelled GnRH analogues. GnRH peptides 
suitability as targeting moiety in drug delivery systems is very rarely compared and results 
coming out from different studies are usually not comparable. Certain cytotoxic agents such 
as daunorubicin have moderate fluorescence, but the emission is usually inadequate for 
detection and quantification at lower concentrations. The cytotoxic effect is also undesirable 
and disadvantageous in certain experiments. Therefore, we conclude that more precise 
binding and cellular uptake studies need for GnRH conjugates with higher fluorescent 
intensity. 
The aim of our study was to investigate the synthesis of [D-Lys
6
(FITC)]-GnRH-I, [D-
Lys
6
(FITC)]-GnRH-II and [Lys
8
(FITC)]-GnRH-III conjugates, demonstrate their usability for 
in vitro research, and compare their tumour targeting efficiency.  
For this purpose, at first the solubility, stability, and permeability of these labelled analogues 
were measured. The cytotoxic effect was tested on NIH/3T3 cells. The cellular uptake was 
quantified by flow cytometer on the GnRH-I-R positive LNCaP, MCF-7, HT-29 and BxPC-3 
tumour cells, among them on the previously not investigated Detroit-562 tumour cells, and on 
the GnRH-I-R negative MDCK cells. Finally the localization of the conjugates was visualised 
by confocal laser scanning microscopy.  
 
Synthesis of FITC labelled GnRH Conjugates  
All GnRH analogues were synthesized manually on H-Rink Amide ChemMatrix® resin using 
standard Fmoc strategy. After completing the synthesis of peptides, the protecting group was 
selectively removed from the side chain of Lys or D-Lys. After the FITC conjugation, the 
conjugates were cleaved form the resins. The conjugates (Figure 1) were purified by semi-
preparative RP-HPLC, and characterized by HPLC-UV and ESI-MS (Table 1). 
The conjugates were identified by the triply charged ions ([M+3H]
3+
). Tandem mass 
spectrometric data (fragment ions) and exact mass determination were used to confirm the 
structures. Based on the chromatographic data the purity of the conjugates were over 98% 
(Figure S1). 
 
 
 
Figure 1. Schematic structures of FITC labelled GnRH-
I (A), GnRH-II (B) and GnRH-III (C) derivatives 
 
Solubility and stability evaluation of FITC-GnRH conjugates  
The solubility parameters of FITC labelled and unlabelled GnRH analogues were compared 
in PBS (pH: 7.4, T: 25°C). Concentrations quantified by HPLC-UV (Figure S2).  
We found that the unlabelled GnRH analogues dissolved readily in PBS, their solubility being 
over 200 µM. Nevertheless, it was observed that the conjugation of FITC decreased the 
solubility of these peptides (Table 2). The solubility of [Lys
8
(FITC)]-GnRH-III remained 
above 200 µM, but the solubility of [D-Lys6(FITC)]-GnRH-I and [D-Lys6(FITC)]-GnRH-II 
decreased significantly. Precipitations could be seen as well. Based on these results, the upper 
concentration for all conjugates was limited to 40 µM in all other experiments. 
Stability of the conjugates was measured in cell culture medium (RPMI) for 24 hours at 37°C. 
During the experiment the stability of all compounds was detected by RP-HPLC, no 
additional peak appeared, and their purity remained higher than 98% (Figure S2). 
 
Permeability of FITC-GnRH conjugates 
Permeability across biological membranes is a key factor in the absorption and distribution of 
conventional drugs, but it is undesired for targeted conjugates. We tested the permeability of 
our conjugates by PAMPA and MDCK permeability assay.  
PAMPA has become a useful tool for predicting drug permeability driven by passive transport 
mechanisms. We used caffeine as positive and fluorescein sodium salt as negative control. 
Compounds were tested at 40 µM concentration, and detected by UV-VIS spectroscopy 
(Figure S3). We found that the conjugates and the fluorescein sodium salt had negligible 
permeability (Table 3). The PAMPA mass retention was the highest at [D-Lys
6
(FITC)]-
GnRH-II and the lowest at [Lys
8
(FITC)]-GnRH-III. This correlates with their estimated 
lipophilicity concluded form RP-HPLC retention times.  
MDCK cell lines provide a useful tool to predict the in vivo absorption of orally administered 
drugs. Compounds were tested at 10 µM concentration by MDCK permeability assay and 
detected by HPLC-UV (Figure S4). We investigated both the „apical to basolateral”, and the 
„basolateral to apical” transport directions. We found that the conjugates cannot penetrate the 
MDCK cell monolayer, detectable peaks were not observed in the receiver chambers  
After these experiments we can conclude that the FITC labelled GnRH conjugates have 
negligible passive permeability. This observation corroborates the presumption, that the 
uptake of the conjugates takes place mainly by active transport mechanisms. 
 
Cytotoxicity of FITC-GnRH conjugates 
We tested the cytotoxicity of the labelled and the unlabelled GnRH analogues on the GnRH-I-
R positive NIH/3T3 (mouse fibroblast) cells at 40 µM concentration. Fluorescein sodium salt 
as negative control and staurosporin as positive control were used. It was indicated that 
neither the peptides nor the conjugates had significant cytotoxic effect after the 24 hours 
treatment (Figure 2). Thereby we suggest that these non-toxic conjugates have lower 
influence on the habitual behaviour of cells, which enable the reliable quantification and 
comparison of these GnRH analogues as targeting moieties. 
 
 Figure 2. Cytotoxicity of the FITC labelled and the unlabelled GnRH analogues on NIH/3T3 cell line. 
Concentration: 40 µM; incubation time: 24 h. Results were presented as SD, N=3. 
 
GnRH-I-R analysis 
The presence of GnRH-I-R has been previously demonstrated in LNCaP (prostate), MCF-7 
(breast), BxPC-3 (pancreas) and HT-29 (colon) tumour cells by other groups [18,32–34]. We 
verified the existence of the GnRH-I-R in our corresponding cell lines, and investigated the 
Detroit-562 human pharynx tumour, the MDCK (dog kidney) and the NIH/3T3 (mouse 
fibroblast) cell lines as well (Figure 3). We used rat hypothalamus lysate as positive control. 
The western blot analysis revealed a clear band at approximately 38 kDa, which correspond to 
the predicted unmodified molecular weight of GNRH-I-R [35]. We found evidence for the 
presence of GnRH-I-R in the Detroit-562 and NIH/3T3 cells, however the MDCK cells do not 
express the human GnRH-I-R. 
 
Figure 3. Western blot analysis of GnRH-I-R 
expression on different cell lines.  
 
Cellular uptake and cell surface GnRH-I-R analysis  
The cell surface GnRH-I-R level was investigated by immunocytochemistry. We detected 
varying levels of GnRH-I-R on the surface of the different, non permeabilized tumour cells. 
No surface GnRH-I-R was found on the non-tumoural MDCK (dog kidney) cells and only 
traces on the BxPC-3 (pancreas) tumour cells (Figure 4). However, permeabilized samples of 
BxPC-3 showed high amount of GnRH-I-R, as revealed by western blot analysis (Figure S5). 
This suggests that these pancreatic cells don’t present GnRH-I-R on their membranes. The 
other tested tumour cell lines express well detectable GnRH-I-R level on their membranes 
(Figure 4). 
Fluorescein sodium salt, the negative control, was found only in traces inside of the cells 
(Figure 4). This observation correlates with the permeability experiment, as fluorescein 
cannot penetrate cell membrane effectively without conjugation.  
Experiments with our conjugates resulted that each of the three GnRH analogues were 
detectable inside of the cells at 10 µM (Figure 4). In the same type of tumour cells the level of 
the three conjugates were similar and correlated with their GNRH-I-R levels. High amount of 
GnRH conjugates were detected in LNCaP (prostate), MCF-7 (breast) and Detroit-562 
(pharynx) tumour cells, lower in HT-29 (colon) and MDCK cells, and found only traces in 
BxPC-3, in correlation with the results of FACS experiments. The high level of GnRH-I-R on 
the surface of Detroit-562 cells was associated with large quantities of GnRH conjugates in 
these cells (Figure 4). These results demonstrate for the first time the high cell surface 
expression of GnRH-I-R and the effective GnRH uptake on human pharynx tumour cells. 
 
Figure 4. Confocal images of LNCaP (prostate), MCF-7 (breast), BxPC-3 (pancreas), HT-29 (colon), Detroit-
562 (pharynx) tumour cell lines and the MDCK (dog kidney) cell line. Treatment with fluorescein sodium salt 
(10 µM), blue stain: nucleus, green stain: fluorescein (A). Human GnRH-I-R visualization by 
immunocytochemistry, blue stain: nucleus; red stain: GnRH-I-R (B). Treatment with conjugates (10 µM), blue 
stain: nucleus; green stain: [D-Lys
6
(FITC)]-GnRH-I (C); [D-Lys
6
(FITC)]-GnRH-II (D); [Lys
8
(FITC)]-GnRH-III 
(E). 
 
Cellular uptake profile of FITC-GnRH conjugates 
The cellular uptake profile of GnRH conjugates was studied by flow cytometer. We found 
that all of the labelled GnRH analogues were detectable in each of the tested cell lines at 10 
µM, in correlation with the confocal microscopy experiments (Figure 5). 
The LNCaP (prostate) showed the highest uptake at 10 µM. The MCF-7 (breast) resulted high 
GnRH uptake also, its efficiency was similar to the Detroit-562 (pharynx). The MDCK (dog 
kidney), BxPC-3 (pancreas) and HT-29 (colon) took up the conjugates moderately (Figure 5). 
We observed that differences between the GnRH analogues were more significant at 1 µM, 
furthermore the different cells preferred different GnRH analogues (Table 4). This 
observation is in context with the “selective signaling theory“, which means that “GnRH 
receptor can assume different conformations which have different selectivity for GnRH 
analogs” [36]. The previously not investigated Detroit-562 cells showed the highest uptake 
for GnRH-I and GnRH-III at 1 µM (Table 4). 
Our results proved better correlation between the uptake efficiency and the surface GnRH-I-R 
level at 1 µM, than 10 µM (Figure 4 and Figure 5). Significant cellular uptake was appeared 
for all conjugates at 10 µM on the GnRH-I-R negative MDCK and on the GnRH-I-R non 
exhibiting BxPC-3 cells also (Figure 5). This suggests the presence of a GnRH-I-R 
independent uptake mechanism on these cell lines and predicts better GnRH-I-R selectivity 
for these conjugates below 10 µM. On the other hand the existence and the concentration 
dependent influence of the putative way is conceivable on other tested cell lines also, that 
should be further examined. This phenomenon correlates with the results were reported by 
Gründker et al. using human ovarian and endometrial cancers [18,22]. 
 
 Figure 5. Uptake profile of [D-Lys
6
(FITC)]-GnRH-I (I), [D-Lys
6
(FITC)]-GnRH-II (II) and [Lys
8
(FITC)]-GnRH-
III (III) conjugates at 1 µM and 10 µM, between the 1 hour and 5 hours incubations. Results were presented as 
SD, N=3. 
 
Conclusions 
Based on our present findings we can state that these novel, selectively labelled, fluorescent 
GnRH derivatives are efficient tools to track and quantify their receptor mediated cellular 
uptake in vitro and predict the corresponding GnRH conjugates drug targeting efficiency in 
vivo. Experiments with these conjugates proved at first time that human pharynx tumours may 
also be promising targets for GnRH based therapy. 
Our results confirm that each of the three GnRH analogues are usable as drug delivery units, 
however different cells prefer different analogues. At the same time, we note that due to the 
lower endocrine activity and better solubility of GnRH-III, it might be preferable in hormone 
independent tumours’ therapy.  
We found that the effectiveness of the cellular uptake depends basically on the type of the 
tumour and on the applied concentration. The cellular uptake of GnRH analogues was well 
correlated with the level of cell surface GnRH-I-R at 1 µM. These results predict that these 
analogues have high GnRH-I-R selectivity below 1 µM. Furthermore, we suppose that the 
uptake of these GnRH peptides could take place not only by the human GnRH-I receptors, 
especially at higher concentrations (10 µM or above), but this unknown active transport 
mechanism should be further examined. 
 
Acknowledgements 
The project was supported by National Research Fund OTKA (K 104045). 
 
References 
1 Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. CA. Cancer J. Clin. 2016; 66: 7–
30; DOI:10.3322/caac.21332. 
2 Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga 
JL, Halmos G. Hypothalamic Hormones and Cancer. Front. Neuroendocrinol. 2001; 22: 
248–291; DOI:10.1006/frne.2001.0217. 
3 Hierowski MT, Altamirano P, Redding TW, Schally AV. The Presence of LHRH-like 
Receptors in Dunning R3327H Prostate Tumors. FEBS Lett 1983; 154: 92–96. 
4 Eidne KA, Flanagan CA, Millar RP. Gonadotropin-Releasing Hormone Binding Sites in 
Human Breast Carcinoma. Science 1985; 229: 989–991. 
5 Montagnani Marelli M, Moretti RM, Januszkiewicz-Caulier J, Motta M, Limonta P. 
Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: A New Rationale for the 
Therapeutical Application of GnRH Analogs in Cancer Patients? Curr Cancer Drug 
Targets 2006; 6: 257–269. 
6 Schally AV, Nagy A. Chemotherapy Targeted to Cancers through Tumoral Hormone 
Receptors. Trends Endocrinol Metab 2004; 15: 300–310; DOI:10.1016/j.tem.2004.07.002. 
7 Nagy A, Schally AV. Targeting of Cytotoxic Luteinizing Hormone-Releasing Hormone 
Analogs to Breast, Ovarian, Endometrial, and Prostate Cancers. Biol Reprod 2005; 73: 
851–859; DOI:10.1095/biolreprod.105.043489. 
8 Schally AV, Nagy A. Cancer Chemotherapy Based on Targeting of Cytotoxic Peptide 
Conjugates to Their Receptors on Tumors. Eur J Endocrinol 1999; 141: 1–14. 
9 Harrison GS, Wierman ME, Nett TM, Glode LM. Gonadotropin-Releasing Hormone and 
Its Receptor in Normal and Malignant Cells. Endocr Relat Cancer 2004; 11: 725–748; 
DOI:10.1677/erc.1.00777. 
10 Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J, 
Monfette G. Treatment of Prostate Cancer with Gonadotropin-Releasing Hormone 
Agonists. Endocr Rev 1986; 7: 67–74. 
11 Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M. Antiproliferative 
Effects of Luteinizing Hormone-Releasing Hormone (LHRH) Agonists on Human 
Androgen-Independent Prostate Cancer Cell Line DU 145: Evidence for an Autocrine-
Inhibitory LHRH Loop. Cancer Res 1994; 54: 4091–4095. 
12 Grundker C, Gunthert AR, Westphalen S, Emons G. Biology of the Gonadotropin-
Releasing Hormone System in Gynecological Cancers. Eur J Endocrinol 2002; 146: 1–14. 
13 Millar RP. GnRHs and GnRH Receptors. Anim. Reprod. Sci. 2005; 88: 5–28; 
DOI:10.1016/j.anireprosci.2005.05.032. 
14 Limonta P, Dondi D, Moretti RM, Maggi R, Motta M. Antiproliferative Effects of 
Luteinizing Hormone-Releasing Hormone Agonists on the Human Prostatic Cancer Cell 
Line LNCaP. J Clin Endocrinol Metab 1992; 75: 207–212; 
DOI:10.1210/jcem.75.1.1320049. 
15 Janáky T, Juhász A, Bajusz S, Csernus V, Srkalovic G, Bokser L, Milovanovic S, Redding 
TW, Rékási Z, Nagy A, Schally AV. Analogues of Luteinizing Hormone-Releasing 
Hormone Containing Cytotoxic Groups. Proc Natl Acad Sci U A 1992; 89: 972–976. 
16 Miyamoto K, Hasegawa Y, Nomura M, Igarashi M, Kangawa K, Matsuo H. Identification 
of the Second Gonadotropin-Releasing Hormone in Chicken Hypothalamus: Evidence That 
Gonadotropin Secretion Is Probably Controlled by Two Distinct Gonadotropin-Releasing 
Hormones in Avian Species. Proc Natl Acad Sci U A 1984; 81: 3874–3878. 
17 White RB, Eisen JA, Kasten TL, Fernald RD. Second Gene for Gonadotropin-Releasing 
Hormone in Humans. Proc Natl Acad Sci U A 1998; 95: 305–309. 
18 Gründker C, Föst C, Fister S, Nolte N, Günthert AR, Emons G. Gonadotropin-Releasing 
Hormone Type II Antagonist Induces Apoptosis in MCF-7 and Triple-Negative MDA-MB-
231 Human Breast Cancer Cells in Vitro and in Vivo. Breast Cancer Res. 2010; 12; 
DOI:10.1186/bcr2606. 
19 Fister S, Gunthert AR, Aicher B, Paulini KW, Emons G, Grundker C. GnRH-II 
Antagonists Induce Apoptosis in Human Endometrial, Ovarian, and Breast Cancer Cells 
via Activation of Stress-Induced MAPKs p38 and JNK and Proapoptotic Protein Bax. 
Cancer Res 2009; 69: 6473–6481; DOI:10.1158/0008-5472.can-08-4657. 
20 Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz-Caulier J, Motta M, Limonta P. 
Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects 
of GnRH-II on Prostate Cancer Cells. J Clin Endocrinol Metab 2009; 94: 1761–1767; 
DOI:10.1210/jc.2008-1741. 
21 Grundker C, Gunthert AR, Millar RP, Emons G. Expression of Gonadotropin-Releasing 
Hormone II (GnRH-II) Receptor in Human Endometrial and Ovarian Cancer Cells and 
Effects of GnRH-II on Tumor Cell Proliferation. J Clin Endocrinol Metab 2002; 87: 1427–
1430; DOI:10.1210/jcem.87.3.8437. 
22 Grundker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G. 
Antiproliferative Effects of the GnRH Antagonist Cetrorelix and of GnRH-II on Human 
Endometrial and Ovarian Cancer Cells Are Not Mediated through the GnRH Type I 
Receptor. Eur J Endocrinol 2004; 151: 141–149. 
23 Szabó I, Bosze S, Orbán E, Sipos E, Halmos G, Kovács M, Mezo G. Comparative in Vitro 
Biological Evaluation of Daunorubicin Containing GnRH-I and GnRH-II Conjugates 
Developed for Tumor Targeting. J. Pept. Sci. 2015; DOI:10.1002/psc.2775. 
24 Sower SA, Chiang YC, Lovas S, Conlon JM. Primary Structure and Biological Activity of 
a Third Gonadotropin-Releasing Hormone from Lamprey Brain. Endocrinology 1992; 132: 
1125–1131. 
25 Lovas S, Palyi I, Vincze B, Horvath J, Kovacs M, Mezo I, Toth G, Teplan I, Murphy RF. 
Direct Anticancer Activity of Gonadotropin-Releasing Hormone-III. J Pept Res 1998; 52: 
384–389. 
26 Mezo I. Synthesis of Gonadotropin-Releasing Hormone III Analogs. Structure- Antitumor 
Activity Relationships. J. Med. Chem. 1997; 40: 3353–3358; DOI:10.1021/jm9700981. 
27 Schreier VN, Petho L, Orbán E, Marquardt A, Petre BA, Mezo G, Manea M. Protein 
Expression Profile of HT-29 Human Colon Cancer Cells after Treatment with a Cytotoxic 
Daunorubicin-GnRH-III Derivative Bioconjugate. PLoS One 2014; 9; 
DOI:10.1371/journal.pone.0094041. 
28 Montagnani Marelli M, Manea M, Moretti RM, Marzagalli M, Limonta P. Oxime Bond-
Linked Daunorubicin-GnRH-III Bioconjugates Exert Antitumor Activity in Castration-
Resistant Prostate Cancer Cells via the Type I GnRH Receptor. Int J Oncol 2015; 46: 243–
253; DOI:10.3892/ijo.2014.2730. 
29 Manea M, Tóvári J, Tejeda M, Schulcz Á, Kapuvári B, Vincze B, Mezo G. In-Vivo 
Antitumour Effect of Daunorubicin-GnRH-III Derivative Conjugates on Colon Carcinoma-
Bearing Mice. Anticancer Drugs 2012; 23: 90–97; DOI:10.1097/CAD.0b013e32834bb6b4. 
30 Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the Porcine LH- and 
FSH-Releasing Hormone. I. The Proposed Amino Acid Sequence. Biochem Biophys Res 
Commun 1971; 43: 1334–1339. 
31 Dong-Ki K, Ji SY, Kaushik M, Jong-Ik H, Kyungjin K, Dongseung S, Younghee A, 
Cheolji L, Byeong-Cheol K, Hyuk BK, Jun C, Jae YS. A Gonadotropin-Releasing 
Hormone-II Antagonist Induces Autophagy of Prostate Cancer Cells. Cancer Res 2009; 69: 
923–931; DOI:10.1158/0008-5472.CAN-08-2115. 
32 Mezo G, Czajlik A, Manea M, Jakab A, Farkas V, Majer Z, Vass E, Bodor A, Kapuvari B, 
Boldizsar M, Vincze B, Csuka O, Kovacs M, Przybylski M, Perczel A, Hudecz F. 
Structure, Enzymatic Stability and Antitumor Activity of Sea Lamprey GnRH-III and Its 
Dimer Derivatives. Peptides 2007; 28: 806–820; DOI:10.1016/j.peptides.2006.12.014. 
33 Aggarwal S, Ndinguri MW, Solipuram R, Wakamatsu N, Hammer RP, Ingram D, Hansel 
W. [DLys(6)]-Luteinizing Hormone Releasing Hormone-Curcumin Conjugate Inhibits 
Pancreatic Cancer Cell Growth in Vitro and in Vivo. Int J Cancer 2011; 129: 1611–1623; 
DOI:10.1002/ijc.26132. 
34 Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M. The Luteinizing 
Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger 
Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway. 
Endocrinology 1999; 140: 5250–5256; DOI:10.1210/endo.140.11.7087. 
35 URL: http://www.ptglab.com/Products/GNRHR-Antibody-19950-1-AP.htm 
36 Millar RP, Pawson AJ, Morgan K, Rissman EF, Lu Z-L. Diversity of Actions of GnRHs 
Mediated by Ligand-Induced Selective Signaling. Front. Neuroendocrinol. 2008; 29: 17–
35; DOI:http://dx.doi.org/10.1016/j.yfrne.2007.06.002. 
 
Supporting Information 
Additional Supporting Information may be found in the online version of this article at the 
publisher’s web site. 
 Table 1. Chromatographic and mass spectrometric data of [D-Lys
6
(FITC)]-GnRH-I, [D-Lys
6
(FITC)]-
GnRH-II and [Lys
8
(FITC)]-GnRH-III 
 
RP-HPLC
a
 ESI-MS
b
 
compound name tR (min) [M+3H]
3+
calc [M+3H]
3+
exp MWexact 
[D-Lys
6
(FITC)]-GnRH-I 9.83 548.23 548.23 1641.68 
[D-Lys
6
(FITC)]-GnRH-II 10.12 566.21 566.21 1695.64 
[Lys
8
(FITC)]-GnRH-III 9.52 550.20 550.20 1647.60 
 a
 Column: Technokroma® Mediterranea Sea C18 column (50 mm x 4.0 mm, 3 µm); gradient: 0 min 
0% B, 12 min 50% B; 12.1 min 90% B and 14 min 90% B; eluents: 0.1% TFA in water (A) and 
acetonitrile (B), flow rate: 1 mL/min; detection: λ= 220 nm 
b
 Molecular weight determination by Waters Q-TOF Premier Mass Spectrometer 
 
  
 Table 2. Solubility of labelled and unlabelled GnRH 
analogues in PBS 
compound 
 
solubility
a
 
µM mg/mL 
D-Lys
6
-GnRH-I > 200 > 0,25 
[D-Lys
6
(FITC)]-GnRH-I 94 ± 7 0,15 
D-Lys
6
-GnRH-II > 200 > 0,26 
[D-Lys
6
(FITC)]-GnRH-II 48 ± 3 0,08 
GnRH-III > 200 > 0,25 
[Lys
8
(FITC)]-GnRH-III > 200 > 0,33 
a
 solvent: PBS; pH: 7.4; temperature: 25°C; upper limit 
of quantification: 200 µM; results were presented as SD, 
N=4
 
 Table 3. Permeability of [D-Lys
6
(FITC)]-GnRH-I, [D-Lys
6
(FITC)]-GnRH-II and [Lys
8
(FITC)]-
GnRH-III 
compound Pe (nm/s)
 a
 R (%)
b
 
[D-Lys
6
(FITC)]-GnRH-I ~0.0 23.7 
[D-Lys
6
(FITC)]-GnRH-II ~0.0 35.1 
[Lys
8
(FITC)]-GnRH-III ~0.0 14.5 
fluorescein sodium salt 0.2 ± 0.1 7.8 
caffeine 19.9 ±0.9 ~0.0 
a
 Pe: Permeability (nm/s); results were presented as SD, N=2 
b
 R: Mass retention (percentage loss of compound due to non-specific binding to the plastic 
surfaces during the permeation assay) 
 
 Table 4. Total uptake of [D-Lys
6
(FITC)]-GnRH-I (I), [D-Lys
6
(FITC)]-GnRH-II (II) and [Lys
8
(FITC)]-GnRH-
III (III) 
cell line 
[D-Lys
6
(FITC)]- 
GnRH-I* 
[D-Lys
6
(FITC)]- 
GnRH-II* 
[Lys
8
(FITC)]- 
GnRH-III* 
1 hour 5 hours 1 hour 5 hours 1 hour 5 hours 
MDCK 0.08±0.06 0.11±0.02 0.04±0.06 0.05±0.01 0.09±0.03 0.15±0.02 
LNCaP 0.20±0.05 0.56±0.10 0.34±0.03 1.11±0.05 0.16±0.02 0.54±0.08 
MCF-7 0.31±0.10 0.57±0.08 0.35±0.13 0.73±0.14 0.24±0.08 0.50±0.07 
BxPC-3 0.14±0.09 0.09±0.05 0.05±0.05 0.07±0.01 0.03±0.04 0.01±0.02 
HT-29 0.10±0.05 0.19±0.07 0.12±0.06 0.21±0.05 0.17±0.02 0.30±0.07 
Detroit-562 0.32±0.02 0.61±0.03 0.27±0.04 0.67±0.03 0.33±0.05 0.82±0.08 
*Applied concentration: 1 µM; incubation time: 1 hour and 5 hours; results were presented as SD, N=3 
 
